CRIS - CIK 0001108205
CURIS INC trades as CRIS. In its fiscal 2025 annual report the company posted revenue of $9.44M, down 13.4% from the prior year and net income of -$7.58M. This page tracks CURIS INC through 1,001 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years CURIS INC's revenue grew from $7.53M to $9.44M, a compound annual growth rate of 2.6%. Net profit margin expanded from -802.6% to -80.3% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| PRE 14A | - | 2026-05-22 |
| Major company event | 8-K | 2026-05-22 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-14 |
| Quarterly report | 10-Q | 2026-05-13 |
| Major company event | 8-K | 2026-05-12 |
| Major company event | 8-K | 2026-05-01 |
| SCHEDULE 13G | - | 2026-04-24 |
The largest companies sharing CURIS INC's SEC industry classification (biological products, (no diagnostic substances)).
CURIS INC reported revenue of $9.44M for fiscal year 2025, a decrease of 13.4% year over year.
In its latest fiscal year CURIS INC reported a net loss of $7.58M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.